TEM — Tempus AI, Inc.

Summary of Tempus AI Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: Core business revenue increased by over 33%, significantly boosted by the acquisition of Ambry.
• Diagnostics Growth: Oncology unit growth was 29%, with a remarkable 56% quarter-over-quarter growth in Minimal Residual Disease (MRD) testing. Hereditary testing showed a 23% unit growth.
• Data Business: Grew by 69% in Q4, with a total contract value exceeding $1.1 billion and a net revenue retention rate of 126%.
• Guidance: Projected revenue for 2026 is $1.59 billion, aligning with a long-term growth expectation of 25%, alongside an anticipated adjusted EBITDA of approximately $65 million.

2. Strategic Updates and Business Highlights

• Acquisition of Ambry: Enhanced Tempus' testing capabilities and broadened its hereditary profile offerings, positioning the company as a comprehensive solution provider in oncology.
• Foundation Model Development: Progressing well, with benchmarks met for AstraZeneca. This model is expected to enhance the insights provided through diagnostics and data services.
• Technology and Data Advantage: Tempus emphasized its unique position due to its extensive proprietary data (over 450 petabytes), which is critical for training AI models and delivering real-time insights to healthcare providers.

3. Forward Guidance and Outlook

• 2026 Expectations: Strong visibility into revenue growth, with data business projected to grow by 40% in Q1. The company is optimistic about maintaining a growth rate of approximately 30% in its core oncology diagnostics and data businesses.
• ASP Projections: Average Selling Prices (ASPs) are expected to rise significantly, potentially exceeding $2,200, driven by the transition to FDA-approved versions of tests and ongoing negotiations with commercial payers.

4. Challenges and Points of Concern

• Sales Force Limitations: Currently, only a small percentage of the sales force is focused on MRD testing, which could limit growth potential in that area until fully unlocked.
• Market Competition: Concerns about traditional AI players entering the healthcare space and how that might impact Tempus' data business.
• Hereditary Testing Growth: Anticipated moderation in growth rates for hereditary testing as the company laps previous share gains, with expectations of high teens growth.

5. Notable Q&A Insights

• Customer Feedback: Clients are reportedly deriving significant value from Tempus' data, leading to increased contract renewals and expansions.
• MRD Testing Potential: The company highlighted that if all sales personnel were selling MRD tests, volumes could hypothetically increase by 20x, indicating strong underlying demand.
• Foundation Model Impact: The foundation model is expected to significantly enhance diagnostic capabilities and client value, with ongoing developments across various medical data types.
• ASP and Gross Margin: While ASP increases are expected to boost gross margins, the company is focused on maintaining broad panel offerings to ensure comprehensive patient care.

Overall, Tempus AI reported strong financial performance in Q4 2025, driven by robust growth in both diagnostics and data services, while also addressing potential challenges and competitive pressures in the evolving healthcare landscape.